Fuyuan Tan, Wenliang Li, Long Qiu, Jie Lyu, Haiyue Peng, Wenbing Ding, Jiali Liao, Yuanyou Yang, Ning Liu, Feize Li
{"title":"89Zr PET imaging guided validation of the medicinal potentiality of UiO-66 based nano drug delivery system","authors":"Fuyuan Tan, Wenliang Li, Long Qiu, Jie Lyu, Haiyue Peng, Wenbing Ding, Jiali Liao, Yuanyou Yang, Ning Liu, Feize Li","doi":"10.1007/s10967-024-09723-z","DOIUrl":null,"url":null,"abstract":"<p>In this work, positron nuclide <sup>89</sup>Zr was introduced to verify the medical feasibility of UiO-66 as a medical nanodrug carrier via positron emission tomography-computed tomography (PET–CT) imaging. A radiopharmaceutical nanodrug, DOX@<sup>89</sup>Zr-UiO-66-PEG-FA, was well constructed through subsequent doxorubicin (DOX) encapsulation and surface PEGylation of UiO-66 nanocarrier radiolabeled with <sup>89</sup>Zr. Subsequently, tumoricidal effect of DOX@<sup>89</sup>Zr-UiO-66-PEG-FA in murine breast cancer (4T1) models had been evaluated. DOX@<sup>89</sup>Zr-UiO-66-PEG-FA has acceptable stability, excellent cargo loading rate (79.28%), pH-stimulated response property and high cancer cell binding affinity. As a result, PET–CT guided anticancer investigations reveal that DOX@<sup>89</sup>Zr-UiO-66-PEG-FA can well suppress tumor growth with satisfactory biosafety.</p><h3 data-test=\"abstract-sub-heading\">Graphic abstract</h3>\n","PeriodicalId":661,"journal":{"name":"Journal of Radioanalytical and Nuclear Chemistry","volume":"100 1","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Radioanalytical and Nuclear Chemistry","FirstCategoryId":"92","ListUrlMain":"https://doi.org/10.1007/s10967-024-09723-z","RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, ANALYTICAL","Score":null,"Total":0}
引用次数: 0
Abstract
In this work, positron nuclide 89Zr was introduced to verify the medical feasibility of UiO-66 as a medical nanodrug carrier via positron emission tomography-computed tomography (PET–CT) imaging. A radiopharmaceutical nanodrug, DOX@89Zr-UiO-66-PEG-FA, was well constructed through subsequent doxorubicin (DOX) encapsulation and surface PEGylation of UiO-66 nanocarrier radiolabeled with 89Zr. Subsequently, tumoricidal effect of DOX@89Zr-UiO-66-PEG-FA in murine breast cancer (4T1) models had been evaluated. DOX@89Zr-UiO-66-PEG-FA has acceptable stability, excellent cargo loading rate (79.28%), pH-stimulated response property and high cancer cell binding affinity. As a result, PET–CT guided anticancer investigations reveal that DOX@89Zr-UiO-66-PEG-FA can well suppress tumor growth with satisfactory biosafety.
期刊介绍：
An international periodical publishing original papers, letters, review papers and short communications on nuclear chemistry. The subjects covered include: Nuclear chemistry, Radiochemistry, Radiation chemistry, Radiobiological chemistry, Environmental radiochemistry, Production and control of radioisotopes and labelled compounds, Nuclear power plant chemistry, Nuclear fuel chemistry, Radioanalytical chemistry, Radiation detection and measurement, Nuclear instrumentation and automation, etc.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
